Annovis Bio (NYSE:ANVS – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Roth Capital in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $3.00 price target on the stock. Roth Capital‘s price objective suggests a potential upside of 303.77% from the stock’s previous close.
Other analysts have also issued reports about the company. Weiss Ratings lowered Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 10th. Wall Street Zen upgraded Annovis Bio from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Canaccord Genuity Group restated a “buy” rating on shares of Annovis Bio in a report on Tuesday, August 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.00.
Check Out Our Latest Stock Analysis on Annovis Bio
Annovis Bio Price Performance
Annovis Bio (NYSE:ANVS – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. As a group, equities research analysts anticipate that Annovis Bio will post -1.32 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Michael Hoffman bought 5,000,000 shares of the stock in a transaction dated Friday, November 6th. The stock was bought at an average price of $1.00 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the director directly owned 8,364,883 shares in the company, valued at approximately $8,364,883. This trade represents a 148.59% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 15.92% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANVS. Empowered Funds LLC bought a new stake in Annovis Bio in the 3rd quarter worth about $42,000. State Street Corp increased its stake in Annovis Bio by 35.5% in the 3rd quarter. State Street Corp now owns 105,335 shares of the company’s stock valued at $134,000 after buying an additional 27,600 shares during the last quarter. Nicholson Wealth Management Group LLC bought a new position in shares of Annovis Bio during the 3rd quarter worth approximately $25,000. StoneX Group Inc. lifted its position in shares of Annovis Bio by 65.9% during the 3rd quarter. StoneX Group Inc. now owns 23,996 shares of the company’s stock worth $30,000 after buying an additional 9,531 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Annovis Bio during the 2nd quarter worth approximately $89,000. 15.83% of the stock is currently owned by hedge funds and other institutional investors.
About Annovis Bio
Annovis Bio is a clinical-stage biotechnology company based in Malvern, Pennsylvania. Founded in 2008, the company researches and develops treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
Further Reading
- Five stocks we like better than Annovis Bio
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
